172 related articles for article (PubMed ID: 8973700)
1. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
[TBL] [Abstract][Full Text] [Related]
2. The use of percent free prostate specific antigen for staging clinically localized prostate cancer.
Pannek J; Rittenhouse HG; Chan DW; Epstein JI; Walsh PC; Partin AW
J Urol; 1998 Apr; 159(4):1238-42. PubMed ID: 9507844
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
4. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
[TBL] [Abstract][Full Text] [Related]
5. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
[TBL] [Abstract][Full Text] [Related]
6. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
Partin AW; Kattan MW; Subong EN; Walsh PC; Wojno KJ; Oesterling JE; Scardino PT; Pearson JD
JAMA; 1997 May; 277(18):1445-51. PubMed ID: 9145716
[TBL] [Abstract][Full Text] [Related]
7. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
[TBL] [Abstract][Full Text] [Related]
8. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.
Thiel R; Pearson JD; Epstein JI; Walsh PC; Carter HB
Urology; 1997 May; 49(5):716-20. PubMed ID: 9145976
[TBL] [Abstract][Full Text] [Related]
9. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.
Aslan G; Irer B; Kefi A; Celebi I; Yörükoğlu K; Esen A
Int Urol Nephrol; 2005; 37(3):511-4. PubMed ID: 16307332
[TBL] [Abstract][Full Text] [Related]
10. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
12. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
13. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
Partin AW; Yoo J; Carter HB; Pearson JD; Chan DW; Epstein JI; Walsh PC
J Urol; 1993 Jul; 150(1):110-4. PubMed ID: 7685418
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
15. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
[TBL] [Abstract][Full Text] [Related]
16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Ennis RD; Flynn SD; Fischer DB; Peschel RE
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):317-22. PubMed ID: 7523342
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
[TBL] [Abstract][Full Text] [Related]
19. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.
Erdem E; Atsü N; Akbal C; Bilen CY; Ergen A; Ozen H
Int Urol Nephrol; 2002; 34(4):519-23. PubMed ID: 14577496
[TBL] [Abstract][Full Text] [Related]
20. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
